Finoriq

Finoriq research workspace

Anixa Biosciences Inc (ANIX) Company Overview

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on. Review ANIX filings, fundamentals, valuation, and ownership on Finoriq.

Company Snapshot

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company also engaged in the development of a vaccine against breast cancer; and the development of a vaccine discovery program to develop additional cancer vaccines to address intractable cancers, including high incidence malignancies in lung, colon, and prostate. Its vaccine technologies focus on the discovery of additional retired proteins that may be associated with other forms of cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

Company
Anixa Biosciences Inc (ANIX)
Ticker
ANIX
Market Cap
$117.7M
Latest Price
$3.4599
Industry
Biotech & Pharma

Open insider transactions

Anixa Biosciences Inc (ANIX) Current Valuation Metrics

Static valuation preview for Anixa Biosciences Inc (ANIX). Market data retrieved 2026-07-09. Filing currency USD.

MetricValueSource
Earnings YieldLatest TTM net income divided by market cap.-9.2%Net Income | TTM Q2 2026
Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap.-6.5%Operating Cash Flow | TTM Q2 2026
Price / BookMarket cap divided by stockholders' equity.7.55xStockholders' Equity | Q2 2026

Live data loads in the app

This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.